CClinicalTrials.gg
RecruitingNCT07614685PROOFUpdated Sep 11, 2026

Phase Resolved Functional Lung MRI and Oscillometry for the Observation of Healthy Lung Function

An observational study in Breathing, Lung Function Decreased and MRI Imaging, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by University of Rochester · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine the relationship of airways resistance measured by oscillometry with ventilation defects measured by Phase Resolved Functional Lung (PREFUL) MRI in healthy human subjects.

02

Conditions studied

  • Breathing
  • Lung Function Decreased
  • MRI Imaging
  • Healthy
03

In context

Respiratory Aspiration

1,092 studies on the registry are indexed under Respiratory Aspiration; 216 are open to participants now.

This study's planned enrollment of 20 is below the median of 65 across 184 observational studies indexed under Respiratory Aspiration.

Browse Respiratory Aspiration studies →

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Up to twenty (20) healthy human subjects will be recruited from the outpatient clinics at the University of Rochester Medical Center and the Mary Parkes Asthma Center.

Inclusion criteria

  • Age 18 years or older
  • Ability to provide consent
  • Willingness to perform MRI and breathing test
  • Must be able to speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Unable or willing to provide consent or perform the required maneuvers for testing.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • All participants

    Device: Airway Oscillometer · Diagnostic Test: Phase Resolved Functional Lung MRI

Interventions

  • DeviceAirway Oscillometer

    The termoflo c-100 Airwave Oscillometer System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).

  • Diagnostic testPhase Resolved Functional Lung MRI

    The Phase Resolved Functional Lung (PREFUL) MRI technique acquires images of the lung so that measures of ventilatory defect percentage can be calculated.

06

What researchers measure

Primary outcomes

  1. Oscillometer

    The oscillometer will collect an airway impedance measurement which is made up of multiple variables.

    Time frame: Single measurement, approximately 1 day

  2. Phase Resolved Functional Lung (PREFUL) MRI

    PREFUL MRI will acquire images of the lungs and a measurement called the ventilatory defect percentage (or VDP) will be calculated.

    Time frame: Single measurement, approximately 1 day

07

Study locations

1 of 1 sites recruiting
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614685
Lead sponsor
University of Rochester
Responsible party
Patrick Donohue (Assistant Professor, University of Rochester) — Principal investigator
First posted
May 29, 2026
Start date
Sep 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Patrick Donohue, MD
Contact
patrick_donohue@urmc.rochester.edu
585-210-9301

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion